The FDA will consider AKAO's lead drug on June 25th.
The stock appears to have put in a solid bottom ahead of that meeting.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
